SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ArQule, Inc. (ARQL)
An SI Board Since April 2003
Posts SubjectMarks Bans Symbol
545 40 0 ARQL
Emcee:  tuck Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
195chuckle, <at a higher frequency of "correct" than other defenses.&gquidditch-1/24/2005
194>> and their execution << Constantly making split second decisions,scaram(o)uche-1/24/2005
193Rick: thanks. It could have been, but I seem to recall that the ceo purchaser wquidditch-1/24/2005
192dunno.... thinking of this??..... finance.yahoo.comscaram(o)uche-1/24/2005
191previous filing, for comparison........ <DOCUMENT> <TYPE>SC 13G <scaram(o)uche-1/24/2005
190for those at yahoo who pop off, but don't know the basics.... the entire fiscaram(o)uche-1/24/2005
189Speaking of insider moves, I'm trying to recall, and can't, the name of quidditch-1/24/2005
188>> All directors and executive officers << They, with the exceptionscaram(o)uche-1/24/2005
187Wilder, yes and yes (:- "to wit" (of which I seem to have a lot fewequidditch-1/24/2005
186The only "insider" that I know of is Chang Li.scaram(o)uche-1/24/2005
185>>if they own less than 5% they never have to file a form 3, 4, or 13, deskeokalani'nui-1/24/2005
184As I remember, all senior executives must file, whether or not they hold 5%.tom pope-1/24/2005
183>>Getting sick of this dribble-it-out morning seller. Looks like a "ltuck-1/24/2005
182ArQule Announces Appointment of William Messenger to the Board of Directors Thurmopgcw-1/21/2005
181Clearly if the efficacy of combo therapy seen in animal studies holds true in huIan@SI-1/13/2005
180Only funny thing for me in the presentation was their focus on a Gemzar + ARQ501former_pgs-1/13/2005
179Many thanks for the clarification. I guess I'm too old to try to do 2 thingIan@SI-1/13/2005
178Roche can opt into 501 after phase II data. That would trigger some type of undiformer_pgs-1/13/2005
177>>Yeah, I hear you. Lots of competition. Vertex, Scios, RPR, Astex, & keokalani'nui-1/13/2005
176Thanks Tuck. You be most accurate. >>Other partnered programs . . . we akeokalani'nui-1/13/2005
175I didn't fully understand Roche's rights/options related to ARQ501. CanIan@SI-1/13/2005
174">> I would guess that a decent deal for ARQ-101 would add upside to tuck-1/13/2005
173>> we already knew Wyeth was going after RA in PI, right? Another compoundscaram(o)uche-1/12/2005
172Listened to the H&Q presentation. Not a whole lot new, but a few details ontuck-1/12/2005
171It's the upside I need - for the 2005 competition, at least.nigel bates-1/10/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News